GLP-1 Medications 101: An Honest Briefing

You have almost certainly had this conversation already — with a friend, a sister, or a clinic advertisement. GLP-1 receptor agonists are the most consequential development in metabolic medicine in decades, and the discourse around them is unusually polarised. This page is neither an endorsement nor a warning. It is a briefing so you can have a better conversation with a doctor.

These are prescription medications. Everything below is background, not advice, and nothing here replaces a clinical assessment.

What they are

GLP-1 is a hormone your gut releases after eating. It stimulates insulin, suppresses glucagon, slows gastric emptying, and acts on appetite centres in the brain. GLP-1 receptor agonists are engineered molecules that mimic it with a much longer duration of action — semaglutide and liraglutide are GLP-1 agonists; tirzepatide additionally acts on the GIP receptor.

Originally developed for type 2 diabetes, several are now approved specifically for weight management, and some have additional approvals for cardiovascular risk reduction.

The subjective experience most people describe is not willpower. It is the disappearance of "food noise" — the constant background negotiation about eating. That is a pharmacological effect on appetite regulation, and it is why these drugs work where advice historically did not.

Why they come up in midlife specifically

The menopause transition brings a shift toward central fat, declining insulin sensitivity, and a metabolic environment where previously effective strategies stop delivering. For women who have been managing weight successfully for thirty years and suddenly cannot, this is often the first thing that genuinely moves.

It is worth naming the other side of that: a drug that suppresses appetite arrives at exactly the life stage when protein intake and muscle mass matter most. That tension is the whole management problem.

Realistic expectations

Trial results vary by drug and dose, but broadly: substantial average weight loss over roughly a year — considerably more than lifestyle intervention alone — with meaningful improvements in blood glucose, blood pressure, and lipids.

Two caveats that get lost:

Weight is regained when treatment stops. In withdrawal studies, most of the lost weight returns over the following year. Practically, these are treatments for a chronic condition, more like blood-pressure medication than a course of antibiotics. Plan for that before you start, financially and otherwise.

A significant portion of the loss is lean mass. Estimates commonly run around a quarter to a third of total weight lost, in line with other rapid weight-loss methods. For a perimenopausal woman already losing muscle and bone, unmanaged lean-mass loss is not a cosmetic issue — it is a fracture-risk and frailty issue two decades out.

If you use one, protect the muscle

This is the part most clinics do not spend enough time on, and where the holistic approach earns its keep.

• Protein first, every meal. 1.2–1.6 g per kg of body weight daily, and eat it at the start of the meal — appetite ends early, so what you eat first is what you actually get.
• Resistance training, twice weekly, non-negotiable. This is the intervention with the best evidence for preserving lean mass during weight loss. It matters more here than in any other context in this whole site.
• Do not chase the fastest possible loss. Slower titration, more preserved muscle.
• Track more than weight. A scale cannot distinguish fat from muscle. Body composition, strength numbers, and measurements tell you whether the loss is the loss you wanted.
• Watch micronutrients and hydration. Eating far less means getting far less of everything, and dehydration drives many of the reported side effects.

Side effects and the real risks

Common: nausea, vomiting, diarrhoea, constipation, reflux. Mostly dose-related, mostly improving over weeks, and the main reason people stop.

Serious but uncommon: pancreatitis, gallbladder disease (rapid weight loss is itself a gallstone risk factor), bowel obstruction, and — in animal studies — thyroid C-cell tumours, which is why they are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.

Contraindicated or requiring caution: pregnancy (and these drugs can reduce the effectiveness of oral contraceptives while also potentially restoring ovulation — an unplanned-pregnancy risk that is genuinely under-discussed), breastfeeding, history of pancreatitis, active gallbladder disease, severe gastroparesis, and a history of eating disorders, where appetite suppression can be actively harmful.

On compounded and grey-market versions: compounded semaglutide, "research peptides" sold online, and unregulated clinic products are not the studied drug. Dosing errors from concentration confusion have caused documented harm. If you use one of these medications, use a regulated product with a prescriber who follows you.

Questions to bring to your doctor

1. Given my history, am I a candidate — and what specifically are we treating?
2. What is the plan for preserving muscle and bone while I lose weight?
3. What happens when I stop? Is this indefinite, and can I afford that?
4. How will you monitor me, and what should make me call you?
5. What are the alternatives, and what would we try first?

The honest summary: these are effective, serious medications with real benefits and real trade-offs. They are not a moral failure and they are not a shortcut around health — they are a tool that works best inside a plan that includes protein, lifting, and someone qualified watching your progress.